Adding the investigational agent masitinib to standard frontline docetaxel significantly reduced the risk of disease progression or death in men with metastatic castration-resistant prostate cancer and baseline alkaline phosphatase levels (ALP) of 250 IU/mL or less.
A secondary analysis of the phase 3 HERO trial showed that relugolix failed to significantly improve castration resistance–free survival versus standard leuprolide n patients with advanced prostate cancer.
Primo Lara, Jr, MD, highlights the multitude of available treatments in frontline renal cell carcinoma, and the need for individualized, multidisciplinary treatment in this setting.
The investigational tubulin inhibitor was also safe and well tolerated at continuous daily dosing.
Dual immune checkpoint blockade with the PD-1 inhibitor tislelizumab and the PD-L1 inhibitor BGB-A333 showed clinical activity in bladder cancer.
The results may help guide treatment selection with immunotherapy versus targeted agents in patients with kidney cancer.
Published: September 29th 2020 | Updated:
Published: October 1st 2020 | Updated:
